Status:
Concluded without agreement
Manufacturer:
Chiesi Canada Corporation
Indication:
Transfusional iron overload due to sickle cell disease or other anemias
Last updated October 27, 2023
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Systemic lupus erythematosus
Last updated October 25, 2023
Status:
Concluded with an LOI
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Unresectable or metastatic uveal melanoma in adult patients who are Human leukocyte antigen (HLA)-A*02:01-positive
Last updated October 23, 2023
Lutathera (lutetium 177 dotatate)
Status:
Concluded with an LOI
Manufacturer:
Advanced Accelerator Applications
Indication:
Unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)-positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance
Last updated October 17, 2023
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Episodic migraine in adults (prevention)
Last updated October 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
Atypical hemolytic uremic syndrome
Last updated October 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH)
Last updated October 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Diabetes mellitus in patients who require insulin for the control of hyperglycemia (normally to be used in regimens together with an intermediate or long-acting insulin), or continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for Trurapi insulin infusion
Last updated October 10, 2023
Status:
Negotiations were not pursued
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Last updated October 6, 2023
Status:
Concluded with an LOI
Manufacturer:
Lupin Pharma Canada Ltd.
Indication:
Ankylosing Spondylitis, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and Polyarticular Juvenile Idiopathic Arthritis
Last updated October 4, 2023